Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of March 2020, with a specific reporting date of March 24, 2020. The registrant is a foreign private issuer based in Jerusalem, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
The primary material change disclosed is the election of new directors to the Company's Board of Directors, as announced in a press release dated March 24, 2020.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document serves solely to incorporate the press release regarding the board composition changes by reference.
Investor Verification Checklist
- Verify the identities and backgrounds of the newly elected directors mentioned in the attached press release (Exhibit 99.1).
- Confirm the effective date of the new board composition.
- Review the Company's Registration Statement on Form F-3 (No. 333-201283) where this exhibit is incorporated.